INM
Income statement / Annual
Last year (2026), InMed Pharmaceuticals Inc's total revenue was $3.18 B,
an increase of 64,167.28% from the previous year.
In 2026, InMed Pharmaceuticals Inc's net income was -$12.56 M.
See InMed Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
06/30/2026 |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
| Operating Revenue |
$3.18 B |
$4.94 M |
$4.60 M |
$4.14 M |
$1.09 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.47 B
|
$3.24 M
|
$3.50 M
|
$2.73 M
|
$545.89 K
|
$0.00
|
$183.09 K
|
$123.23 K
|
$122.88 K
|
$96.12 K
|
| Gross Profit |
$709.84 M
|
$1.71 M
|
$1.10 M
|
$1.40 M
|
$543.55 K
|
$0.00
|
-$183.09 K
|
-$123.23 K
|
-$122.88 K
|
-$96.12 K
|
| Gross Profit Ratio |
0.22
|
0.35
|
0.24
|
0.34
|
0.5
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$15.13 M
|
$2.85 M
|
$3.22 M
|
$3.73 M
|
$7.28 M
|
$6.62 M
|
$5.81 M
|
$4.30 M
|
$2.01 M
|
$573.72 K
|
| General & Administrative Expenses |
$1.88 B
|
$6.56 M
|
$5.80 M
|
$5.85 M
|
$6.87 M
|
$5.55 M
|
$3.16 M
|
$6.00 M
|
$3.23 M
|
$2.79 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.33 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.88 B
|
$6.56 M
|
$5.80 M
|
$5.85 M
|
$6.87 M
|
$5.55 M
|
$3.16 M
|
$6.00 M
|
$6.85 M
|
$2.79 M
|
| Other Expenses |
-$1.89 B
|
$212.84 K
|
$219.60 K
|
$202.25 K
|
$185.66 K
|
$0.00
|
$0.00
|
$3.22 M
|
$0.00
|
$75.22 K
|
| Operating Expenses |
$9.19 M
|
$9.62 M
|
$9.24 M
|
$9.78 M
|
$14.34 M
|
$12.17 M
|
$8.97 M
|
$13.52 M
|
$8.85 M
|
$3.44 M
|
| Cost And Expenses |
$9.90 M
|
$12.86 M
|
$12.73 M
|
$12.51 M
|
$14.88 M
|
$12.17 M
|
$9.15 M
|
$13.52 M
|
$8.98 M
|
$3.44 M
|
| Interest Income |
$244.97 K
|
$156.54 K
|
$721.97 K
|
$652.37 K
|
$123.72 K
|
$16.02 K
|
$125.89 K
|
$429.91 K
|
$92.11 K
|
$0.00
|
| Interest Expense |
$10.70 K
|
$373.11 K
|
$0.00
|
$0.00
|
$0.00
|
$360.35 K
|
$18.62 K
|
$0.00
|
$0.00
|
$495.17
|
| Depreciation & Amortization |
$708.36 K
|
$534.73 K
|
$604.52 K
|
$596.00 K
|
$511.79 K
|
$197.03 K
|
$183.09 K
|
$94.72 K
|
$117.92 K
|
$75.22 K
|
| EBITDA |
-$9.19 M |
-$7.26 M |
-$7.06 M |
-$7.34 M |
-$18.09 M |
-$12.12 M |
-$8.76 M |
-$10.26 M |
-$8.86 M |
-$3.36 M |
| EBITDA Ratio |
-0
|
-1.47
|
-1.54
|
-1.77
|
-16.6
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0
|
-1.6
|
-1.77
|
-2.03
|
-12.66
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.48 M
|
-$244.14 K
|
$465.98 K
|
$444.27 K
|
-$4.81 M
|
-$478.14 K
|
$211.71 K
|
$264.60 K
|
$92.41 K
|
-$98.15 K
|
| Income Before Tax |
-$11.37 M
|
-$8.16 M
|
-$7.67 M
|
-$7.93 M
|
-$18.60 M
|
-$12.65 M
|
-$8.94 M
|
-$13.26 M
|
-$8.89 M
|
-$4.47 M
|
| Income Before Tax Ratio |
-0
|
-1.65
|
-1.67
|
-1.92
|
-17.07
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$7.10 K
|
$13.10 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$12.56 M
|
-$8.16 M
|
-$7.68 M
|
-$7.95 M
|
-$18.60 M
|
-$12.65 M
|
-$8.94 M
|
-$10.01 M
|
-$8.89 M
|
-$3.44 M
|
| Net Income Ratio |
-0
|
-1.65
|
-1.67
|
-1.92
|
-17.07
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.12 |
-8.36 |
-20.14 |
-64.92 |
-16582 |
-938.91 |
-1161.21 |
-1264.97 |
-1032.12 |
-810.55 |
| EPS Diluted |
-3.12 |
-8.36 |
-20.14 |
-64.92 |
-16582 |
-938.91 |
-1161.21 |
-1264.97 |
-1032.12 |
-810.55 |
| Weighted Average Shares Out |
$4.16 M
|
$975.99 K
|
$381.05 K
|
$122.42 K
|
$1.12 K
|
$13.44 K
|
$10.44 K
|
$10.38 K
|
$8.63 K
|
$5.87 K
|
| Weighted Average Shares Out Diluted |
$4.16 M
|
$975.99 K
|
$381.05 K
|
$122.42 K
|
$1.12 K
|
$13.44 K
|
$10.44 K
|
$10.38 K
|
$8.63 K
|
$5.87 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
